Bepirovirsen shows significant functional cure rates in hepatitis B trials
GSK's investigational therapy, bepirovirsen, met primary endpoints in phase 3 trials for chronic hepatitis B, showing significant functional cure rates. The trials targeted patients with low baseline HBsAg levels and demonstrated a major advancement in treatment efficacy against a virus affecting over 250 million people worldwide.
Bepirovirsen, an investigational therapy developed by GSK, has shown significant functional cure rates in global phase 3 clinical trials for chronic hepatitis B (CHB). The trials, known as B-Well 1 and B-Well 2, revealed that bepirovirsen met its primary endpoints, demonstrating a statistically significant improvement in functional cure rates when compared to the current standard of care. This finding is particularly important, as CHB is a leading cause of liver cancer, impacting more than 250 million individuals worldwide. The results could transform treatment strategies for this disease, marking a pivotal moment in the management of hepatitis B.
Enjoyed this story?
Show the newsroom a little love — one tap per reader.
Noah believes good news, told well, can change how we see the world.
Be part of the good
Stories like this start with people who care. Share it, or submit your own uplifting story to inspire millions today.
